EP3863615A4 - Methods for the treatment of solid tumor cancers using illudins and biomarkers - Google Patents

Methods for the treatment of solid tumor cancers using illudins and biomarkers Download PDF

Info

Publication number
EP3863615A4
EP3863615A4 EP19872565.7A EP19872565A EP3863615A4 EP 3863615 A4 EP3863615 A4 EP 3863615A4 EP 19872565 A EP19872565 A EP 19872565A EP 3863615 A4 EP3863615 A4 EP 3863615A4
Authority
EP
European Patent Office
Prior art keywords
illudins
biomarkers
treatment
methods
solid tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19872565.7A
Other languages
German (de)
French (fr)
Other versions
EP3863615A1 (en
Inventor
Aditya KULKAMI
Yuvanesh VEDARAJU
Umesh KATHAD
Arun ASAITHAMBI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantern Pharma Inc
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of EP3863615A1 publication Critical patent/EP3863615A1/en
Publication of EP3863615A4 publication Critical patent/EP3863615A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19872565.7A 2018-10-14 2019-10-14 Methods for the treatment of solid tumor cancers using illudins and biomarkers Pending EP3863615A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745382P 2018-10-14 2018-10-14
PCT/US2019/056039 WO2020081414A1 (en) 2018-10-14 2019-10-14 Methods for the treatment of solid tumor cancers using illudins and biomarkers

Publications (2)

Publication Number Publication Date
EP3863615A1 EP3863615A1 (en) 2021-08-18
EP3863615A4 true EP3863615A4 (en) 2022-08-03

Family

ID=70284107

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19872565.7A Pending EP3863615A4 (en) 2018-10-14 2019-10-14 Methods for the treatment of solid tumor cancers using illudins and biomarkers

Country Status (6)

Country Link
EP (1) EP3863615A4 (en)
JP (1) JP2022513349A (en)
CN (1) CN113194934A (en)
AU (1) AU2019361781A1 (en)
CA (1) CA3116552A1 (en)
WO (1) WO2020081414A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021267944A1 (en) * 2020-05-08 2023-01-19 Lantern Pharma Inc. Method for treating pancreatic cancer
AU2021383177A1 (en) * 2020-11-18 2023-07-06 Lantern Pharma Inc. Cancer drug sensitivity determining markers
EP4274662A2 (en) * 2021-01-08 2023-11-15 Lantern Pharma Inc. Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene
MX2024001314A (en) * 2021-07-29 2024-04-30 Lantern Pharma Inc Treating cancers with combinations of parp inhibitor and acylfulvenes.
AU2022317139A1 (en) * 2021-07-29 2024-03-14 Lantern Pharma Inc. Treating cancers with combinations of spironolactone and acylfulvenes
WO2024016014A2 (en) * 2022-07-15 2024-01-18 Lantern Pharma Inc. Method for treating breast cancers and parp resistant breast cancers
CN116287275B (en) * 2023-04-10 2024-04-05 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Use of PTGR1 as a CDK4/6 inhibitor and metformin combination guide marker
CN117233391A (en) * 2023-08-28 2023-12-15 南方医科大学南方医院 Biomarker for predicting curative effect of gastric cancer immunotherapy and/or chemotherapy and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019308A2 (en) * 2005-08-03 2007-02-15 The Regents Of The University Of California Illudin analogs useful as anticancer agents
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2018170230A1 (en) * 2017-03-15 2018-09-20 Memorial Sloan Kettering Cancer Center Diagnosis & treatment of ercc3-mutant cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113824A2 (en) * 2004-05-14 2005-12-01 Zhenghe Wang Protein tyrosine phosphatase mutations in cancers
JP5429735B2 (en) * 2009-03-25 2014-02-26 富士フイルム株式会社 Esophageal cancer detection method and inhibitor
US8901110B2 (en) * 2012-01-13 2014-12-02 Celgene Corporation Use of biomarkers in methods for the treatment of hepatocellular carcinoma
US10285955B2 (en) * 2014-04-10 2019-05-14 Af Chemicals, Llc Affinity medicant conjugate
CA3194672A1 (en) * 2014-04-10 2015-10-15 Af Chemicals, Llc Affinity medicant conjugates
WO2015200823A1 (en) * 2014-06-26 2015-12-30 Institute For Systems Biology Markers and therapeutic indicators for glioblastoma multiforme (gbm)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019308A2 (en) * 2005-08-03 2007-02-15 The Regents Of The University Of California Illudin analogs useful as anticancer agents
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2018170230A1 (en) * 2017-03-15 2018-09-20 Memorial Sloan Kettering Cancer Center Diagnosis & treatment of ercc3-mutant cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARINA TANASOVA ET AL: "Chemistry and Biology of Acylfulvenes: Sesquiterpene-Derived Antitumor Agents", CHEMICAL REVIEWS, vol. 112, no. 6, 6 April 2012 (2012-04-06), US, pages 3578 - 3610, XP055665990, ISSN: 0009-2665, DOI: 10.1021/cr2001367 *
See also references of WO2020081414A1 *
STAAKE MICHAEL D ET AL: "Hydroxyurea derivatives of irofulven with improved antitumor efficacy", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 7, 13 February 2016 (2016-02-13), pages 1836 - 1838, XP029453930, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2016.02.028 *

Also Published As

Publication number Publication date
WO2020081414A1 (en) 2020-04-23
CN113194934A (en) 2021-07-30
AU2019361781A1 (en) 2021-06-03
EP3863615A1 (en) 2021-08-18
JP2022513349A (en) 2022-02-07
CA3116552A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
EP3863615A4 (en) Methods for the treatment of solid tumor cancers using illudins and biomarkers
EP3707158A4 (en) Cancer biomarkers and methods of use thereof
EP3894392A4 (en) Compositions and methods for the treatment of cancer
EP3580560A4 (en) Methods for the detection and treatment of lung cancer
EP3883580A4 (en) Methods of treating cancers
EP3775877A4 (en) Cancer serum biomarkers and methods of use thereof
EP3600393A4 (en) Combination therapy for the treatment of solid and hematological cancers
EP3801563A4 (en) Materials and methods for treating cancer
IL285807A (en) Immunotherapy for the treatment of cancer
EP3787625A4 (en) Methods of treating cancer
EP3775171A4 (en) Methods of treating minimal residual cancer
EP3820492A4 (en) Apmv and uses thereof for the treatment of cancer
EP3870104A4 (en) Methods and materials for treating cancer
EP3873205A4 (en) Materials and methods for treating cancer
EP3860610A4 (en) Combination therapy for the treatment of cancer
EP3673267A4 (en) Methods of diagnosing and treating lung cancer
EP3897649A4 (en) Combination therapy of solid cancer
EP3908650A4 (en) Methods of treating cancer
EP3897650A4 (en) Combination therapy for the treatment of cancer
EP3781215A4 (en) Methods of treating cancer
EP3852816A4 (en) Methods of treating cancer
EP3849544A4 (en) Combination therapy for the treatment of prostate cancer
EP3802851A4 (en) Materials and methods for treating stress-related disorders and cancer
EP3773625A4 (en) Methods and materials for treating cancer
EP4072561A4 (en) Methods of treating cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210514

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060097

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220630

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/6886 20180101ALI20220627BHEP

Ipc: A61P 35/00 20060101ALI20220627BHEP

Ipc: A61K 31/17 20060101ALI20220627BHEP

Ipc: C12Q 1/686 20180101ALI20220627BHEP

Ipc: C07C 239/14 20060101ALI20220627BHEP

Ipc: A61K 31/122 20060101AFI20220627BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240710